Reata Pharma (RETA) Misses Q4 EPS by 76c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Reata Pharmaceuticals (RETA) PT Raised to 'Street High' $362 at Stifel
February 20, 2020 10:22 AM ESTStifel analyst Adam Walsh raised the price target on Reata Pharmaceuticals (NASDAQ: RETA) to 'Street High' $362.00 (from $305.00) while maintaining a Buy rating.
... More